Scientists probe ancient brain pathway to unlock movement after spinal injury
NCT ID NCT04967274
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study investigates the reticulospinal system, an ancient part of the brain that controls posture, walking, and reaching. Researchers will use loud sounds and brain stimulation to test how this system works in healthy people and those with spinal cord injury. The goal is to understand how the brain rewires itself after injury, which could guide future rehabilitation therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal how the brain's reticulospinal system helps people with spinal cord injury regain movement, pointing toward new rehabilitation strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to understand movement control, not to test a therapy. Results may not directly lead to new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Balgrist University Hospital
RECRUITINGZurich, 8008, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test